Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00855738CT.gov A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Focal Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tiagabine (this asset) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Approved | BB · 68 |
| Eslicarbazepine Acetate | Sumitomo Pharma America, Inc. | P4 | A |
| Pregabalin | Yung Shin Pharm. Ind. Co., Ltd. | P4 | A |
| Topiramate | Mario Negri Institute for Pharmacological Research | P4 | A |
| Lacosamide | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | P4 | A |
| Lamotrigine | Dhaka Medical College | P4 | BBB |
| Cenobamate | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Gabapentin | Mario Negri Institute for Pharmacological Research | P4 | BBB |
| Oxcarbazepine | Mario Negri Institute for Pharmacological Research | P4 | BBB |
+42 more in the Focal Epilepsy cohort
Other indications for Tiagabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy | — | P4 | B · 59 |
| Schizophrenia | — | P3 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tiagabine in Focal Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tiagabine-focal-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →